New targets bring hope in squamous cell lung cancer: Neurotrophic tyrosine kinase gene fusions Article

Rolfo, C, Raez, L. (2017). New targets bring hope in squamous cell lung cancer: Neurotrophic tyrosine kinase gene fusions . LABORATORY INVESTIGATION, 97(11), 1268-1270. 10.1038/labinvest.2017.91

cited authors

  • Rolfo, C; Raez, L

authors

abstract

  • Neurotrophic tyrosine kinase genes encode for the Trk-family proteins TrkA, TrkB, and TrkC, which have an important role in the development of the nervous system; however, they have been identified as oncogenic fusions in solid tumors (NTK-1, NTRK-2, and NTRK-3) and are associated with poor survival in lung cancer. These three new fusions can be detected by fluorescent in situ hybridization or next-generation sequencing in less than 5% of the lung tumors. There are several ongoing clinical trials of NTRK oncogenes in lung cancer and other tumors. The agents entrectinib (RXDX-101), a multi-kinase small molecule inhibitor that selectively inhibits NTRK1, NTRK2, and NTRK3, ROS1 and ALK, and LOXO-101, an ATP-competitive pan-NTRK inhibitor, have shown responses in patients with lung cancer with an acceptable toxicity profile. Although these oncogenic fusions are not very prevalent, the high prevalence of lung cancer makes these findings very relevant and suggests the feasibility of these oncogenes as targets in lung cancer. New data from Ozono and collaborators presented in this issue suggest that BDNF/TrkB signal promotes proliferating migratory and invasive phenotypes and cellular plasticity in squamous cell carcinoma (SCC) of the lung but that it also represents a druggable target that may bring hope to squamous lung cancer patients.

publication date

  • November 1, 2017

published in

Digital Object Identifier (DOI)

start page

  • 1268

end page

  • 1270

volume

  • 97

issue

  • 11